A p110δ-specific inhibitor combined with bortezomib blocks drug resistance properties of EBV-related B cell origin cancer cells via regulation of NF-kappa B
- Authors
- Park, Ga Bin; Chung, Yoon Hee; Jeong, Jee-Yeong; Kim, Daejin
- Issue Date
- May-2017
- Publisher
- SPANDIDOS PUBL LTD
- Keywords
- CAL-101; bortezomib; phosphoinositide 3-kinase; multiple myeloma; cancer stem cell; Epstein-Barr virus
- Citation
- INTERNATIONAL JOURNAL OF ONCOLOGY, v.50, no.5, pp 1711 - 1720
- Pages
- 10
- Journal Title
- INTERNATIONAL JOURNAL OF ONCOLOGY
- Volume
- 50
- Number
- 5
- Start Page
- 1711
- End Page
- 1720
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/4498
- DOI
- 10.3892/ijo.2017.3923
- ISSN
- 1019-6439
1791-2423
- Abstract
- Epstein-Barr virus (EBV) infection is closely related to carcinogenesis of various cancers, and is also associated with the development of drug resistance in cancer stem cells. However, in EBV-positive cancer cells, the mechanistic details of the downstream signaling and the connection of PI3K with the NF-kappa B pathway for development of drug resistance remain controversial. Diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM) cells infected by EBV display drug resistance-related proteins (MDR1, MRP1 and MRP2) and stem cell markers (OCT4 and SOX2). EBV-infected HT (HT/EBV) and H929 (H929/EBV) cells activated p110 delta expression, but downregulated the expression of p110 alpha and p110 beta. A combination of CAL-101, a p110 delta-specific inhibitor, with bortezomib treatment of HT/EBV cells synergistically suppressed proliferation, reduced levels of drug resistance-related proteins, activated caspase cleavage and recovered expression of p110 alpha/p110 beta. Additionally, co-treatment with CAL-101 and bortezomib attenuated the expression of OCT4 and SOX2 via inhibition of activated NF-kappa B. Co-treatment with CAL-101 and bortezomib also attenuated drug resistance and NF-kappa B activity of EBV-infected H929 cells. Our results provide supportive evidence for the clinical application of CAL-101 and bortezomib to treat EBV-infected hematologic cancer.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > College of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/4498)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.